Ternary Therapeutics, based at Stevenage Bioscience Catalyst secures €4.1 million seed funding to advance AI-designed molecular glues

Ternary Therapeutics has raised €4.1 million in seed funding to develop an AI-driven platform for the design of molecular glues, a promising modality in drug discovery. The round was led by daphni, with participation from Pace Ventures and UK Innovation & Science Seed Fund, managed by Future Planet Capital.

Molecular glues are an emerging class of therapeutics that enable the targeting of proteins previously considered undruggable by inducing novel protein–protein interactions. Historically, many have been identified through chance rather than deliberate design.

Ternary Therapeutics is developing a platform that combines physics-informed artificial intelligence with experimental validation, with the aim of enabling a more systematic and scalable approach to molecular glue discovery.